Open-label, active-control, phase 2/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma.

被引：0
|
作者：
Cobb, Patrick Wayne
Zhou, Heng
Nahar, Akash
Marinello, Patricia
机构：
[1] St Vincent Healthcare Canc Ctr Montana, Billings, MT USA
[2] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7592
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
    Ozcan, Muhit
    Lee, Seung Tae
    Mensah, Felix
    Modi, Dipenkumar
    Fossa, Alexander
    Kim, Won Seog
    Paszkiewicz-Kozik, Ewa
    Sawalha, Yazeed
    Sevindik, Omur Gokmen
    Norasetthada, Lalita
    Santoro, Armando
    Pathiraja, Kumudu
    Chakraborty, Samhita
    Marinello, Patricia
    Lavie, David
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Murayama, Kayoko
    Kiguchi, Toru
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Rai, Shinya
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Fukushima, Koji
    Terui, Yasuhito
    ANNALS OF HEMATOLOGY, 2022, 101 (05) : 979 - 989
  • [33] Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
    Sehn, Laurie H.
    Matasar, Matthew J.
    Flowers, Christopher R.
    Kamdar, Manali
    McMillan, Andrew K.
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Croft, Brandon
    Hirata, Jamie
    Cheng, Ji
    Ku, Grace
    Herrera, Alex F.
    BLOOD, 2019, 134
  • [34] Phase 1/2 Trial of Acalabrutinib Plus Pembrolizumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 9 - 10
  • [35] Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study
    Locatelli, Franco
    Mauz-Koerholz, Christine
    Neville, Kathleen
    Llort, Anna
    Beishuizen, Auke
    Daw, Stephen
    Pillon, Marta
    Aladjidi, Nathalie
    Klingebiel, Thomas
    Landman-Parker, Judith
    Medina-Sanson, Aurora
    August, Keith
    Sachs, Jessica
    Hoffman, Kristen
    Kinley, Judith
    Song, Sam
    Song, Gregory
    Zhang, Stephen
    Suri, Ajit
    Gore, Lia
    LANCET HAEMATOLOGY, 2018, 5 (10): : E450 - E461
  • [36] A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Hoyle, Margaret
    Paccagnella, Luisa
    BLOOD, 2023, 142
  • [37] Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel
    Strati, Paolo
    Watson, Grace
    Horowitz, Sandra B.
    Nair, Ranjit
    Rodriguez, Maria Alma
    Steiner, Raphael Eric
    Fayad, Luis
    Westin, Jason R.
    Neelapu, Sattva S.
    BLOOD, 2020, 136
  • [38] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
    Caimi, Paolo F.
    Ai, Weiyun
    Alderuccio, Juan Pablo
    Ardeshna, Kirit M.
    Hamadani, Mehdi
    Hess, Brian
    Kahl, Brad S.
    Radford, John
    Solh, Melhem
    Stathis, Anastasios
    Zinzani, Pier Luigi
    Havenith, Karin
    Feingold, Jay
    He, Shui
    Qin, Yajuan
    Ungar, David
    Zhang, Xiaoyan
    Carlo-Stella, Carmelo
    LANCET ONCOLOGY, 2021, 22 (06): : 790 - 800
  • [39] A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Crombie, Jennifer L.
    Kim, Austin I.
    Bartlett, Nancy L.
    Redd, Robert A.
    Patterson, Victoria
    Carey, Celeste
    Balasubramanian, Sobana
    Odejide, Oreofe O.
    Merryman, Reid W.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Fisher, David C.
    Herrera, Alex F.
    Davids, Matthew S.
    Shipp, Margaret A.
    Armand, Philippe
    Shouse, Geoffrey P.
    BLOOD, 2023, 142
  • [40] Phase 1 clinical study ofAtacicept in patients with relapsed and refractory B-cell lymphoma.
    Ansell, Stephen
    Witzig, Thomas E.
    Novak, Anne
    Inwards, David James
    Porrata, Luis
    Ythier, A.
    Ferrande, L.
    Nestorov, I.
    DeVries, T.
    Sievers, Eric
    BLOOD, 2006, 108 (11) : 770A - 770A
12345